291.72
United Therapeutics Corp stock is traded at $291.72, with a volume of 641.28K.
It is up +1.69% in the last 24 hours and down -4.46% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$286.88
Open:
$287.98
24h Volume:
641.28K
Relative Volume:
1.22
Market Cap:
$12.69B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
11.64
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
+5.52%
1M Performance:
-4.46%
6M Performance:
-18.41%
1Y Performance:
-4.68%
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
291.72 | 12.69B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
63.35 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
155.06 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.45 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.06 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
Feb-05-24 | Initiated | Leerink Partners | Outperform |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Dec-06-22 | Initiated | UBS | Buy |
Dec-05-22 | Initiated | Goldman | Sell |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-20-22 | Reiterated | BofA Securities | Underperform |
Sep-19-22 | Resumed | Wedbush | Outperform |
Feb-11-22 | Initiated | BTIG Research | Neutral |
Jul-14-21 | Upgrade | Argus | Hold → Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-03-19 | Initiated | BofA/Merrill | Underperform |
Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
May-17-19 | Upgrade | UBS | Sell → Neutral |
May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Feb-22-18 | Reiterated | Barclays | Underweight |
Jan-18-18 | Resumed | Credit Suisse | Underperform |
Dec-27-17 | Reiterated | Wedbush | Outperform |
Apr-27-17 | Reiterated | Wedbush | Outperform |
Mar-30-17 | Initiated | UBS | Sell |
Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener
United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com
United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News
Treprostinil Saga Continues - JD Supra
United Therapeutics president sells shares worth $3.7 million - MSN
Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa
Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com
United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World
United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus
Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga
United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus
United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus
Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360
United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey
Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus
Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals
Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News
Construction underway for new United Therapeutics facility in Stewartville - KTTC News
Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin
Interesting UTHR Put And Call Options For July 18th - Nasdaq
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance
UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360
Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com
Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus
Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance
Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey
Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance
3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance
MANNKIND CORP SEC 10-Q Report - TradingView
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria
TD Cowen maintains United Therapeutics stock Buy rating - Investing.com
3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
MAHON PAUL A | EVP & GENERAL COUNSEL |
Jun 12 '25 |
Sale |
279.96 |
11,000 |
3,079,514 |
36,781 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):